Cerebrolysin
A brain peptide mix used after stroke or head injury, given as an IV drip in clinics abroad.
- What it is
- A mix of peptides made from pig brain
- Is it FDA-approved?
- Not in the US, but approved in ~50 countries abroad
- How strong is the proof?
- Decent. Many trials, but results are mixed
- How you take it
- An IV drip in a clinic, daily for 10 to 20 days
- Typical result
- Modest help recovering from stroke or injury
- Biggest catch
- The real product is one brand; copies are fakes
Any word with a dotted underline is a science word — tap it for a plain-English meaning.
In plain words.
Cerebrolysin is not one . It is a mix of small peptides and amino acids. They are made from pig brain tissue.
It has been used since 1954, mostly in Europe and Asia, for stroke and dementia care. One company, Ever Neuro Pharma, has made it the whole time.
It is approved in about 50 countries. It is not in the US. It is given by IV, meaning a drip into a vein.
What people use it for.
People use it to recover from brain problems. The main ones are stroke, a head injury (called TBI), and some types of dementia.
It is meant for a specific event, like right after a stroke. Then you take a short course.
It is not a daily "smart drug" you take for years. The benefit shows up around the event, not as a general brain booster.
Does it actually work?
It has the most trial data of any on this site. The results are real but mixed.
There have been many phase 3 trials in stroke, dementia, and head injury. Cochrane, a respected group that reviews trials, looked at it. They found possible benefit in early stroke, but the effect is modest.
So the honest read: this is well-studied, and it may help a little after a stroke or injury. But it is not a miracle, and the benefit fades for general use outside that window.
what you’ve probably heard.
The claims floating around online, and how true they actually are.
“It's a heavy-hitting nootropic that makes you sharper.”
overblownThe benefit shows up around a brain event like a stroke or head injury, then fades for general use. As a daily smart drug it is not worth it.
“It repairs your brain after a stroke.”
half trueIt has the most trial data of any here, and Cochrane found a possible benefit in early stroke. But the effect is modest and the results across trials are mixed.
“Just shoot it in your glute at home like the clinics do.”
not quiteEvery trial gave it as an IV drip with a doctor watching. The at-home muscle shot gets the drug in, but it is not the route that was studied.
“All cerebrolysin is the same, buy the cheapest.”
mythIt is a pig-brain mix, not a single molecule, so the brand is the product. If it is not Ever Neuro Pharma, it is a different thing in a similar vial.
How you take it.
In the trials, it was always given by IV drip in a clinic. The dose was 10 to 30 mL a day for 10 to 20 days.
That is a short course tied to a brain event, not a long-term habit. A doctor watches you during the drip.
Important: people who import it often inject it into a muscle (the glute) at home instead. That gets the drug into the body, but it skips the clinic monitoring the trials had. The home version is not the studied one.
What to watch out for.
Side effects are uncommon and mild in the trials. That is one reason it has stayed in use so long. The catches here are less about side effects and more about what it is and how it is given.
- It is made from pig brain. Skip it if you are allergic to pig products. There is no other source, so skip it if you avoid pork for religious or personal reasons.
- Skip it if you are pregnant.
- The real trial route is an IV drip with a doctor watching. Doing it yourself at home is not the tested way.
Talk to a real doctor before trying it. We are not your doctor.
Where people get it.
Here are the ways people get it, from safest to riskiest.
- Brand (Ever Neuro Pharma). The only real version. At European pharmacies it runs about $120 to $220 a course. US import is legally restricted.
- . Not possible. It is a pig-brain mix, not a single molecule, so pharmacies cannot copy it.
- Research-only (). Avoid. Since the brand IS the molecule, " Cerebrolysin" is by definition a different product in a similar vial.
- . vendors do not carry it. The practical cheap path is medical travel: getting the real product at a clinic abroad.
Ask your source four things before you pay. (1) Brand and country and pharmacy registration. If it is not "Ever Neuro Pharma," it is not Cerebrolysin. (2) The route. Trial-grade is an IV drip in a clinic. (3) That it is pig-sourced. (4) That it was made within the last 90 days.
Our honest take.
This one earns its place only when it is tied to a real event. For an early stroke or a moderate head injury, in a country where it is sold, the trial course (an IV drip for 10 to 20 days) under a treating neurologist is a fair add-on.
As a daily brain booster, it is not worth it. The benefit washes out outside the event window, and the at-home muscle shot is not the studied route.
If you find yourself running it month after month as maintenance, that is a habit, not a plan. Pick a with real long-term data instead.
The studies behind this.
We read the research so you don't have to. Here's where the facts on this page come from.
- 01Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2023;10(10):CD007026. PMID: 37818733.
- 02Cui S, et al. Cerebrolysin for vascular dementia. The Cochrane database of systematic reviews. 2019;2019(11). PMID: 31710397.
- 03Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2020;7(7):CD007026. PMID: 32662068.
- 04Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2017;4(4):CD007026. PMID: 28430363.
- 05Brainin M. Cerebrolysin: a multi-target drug for recovery after stroke. Expert review of neurotherapeutics. 2018;18(8):681-687. PMID: 30004268.
- 06Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2015(6):CD007026. PMID: 26083192.
- 07Chen N, et al. Cerebrolysin for vascular dementia. The Cochrane database of systematic reviews. 2013(1):CD008900. PMID: 23440834.
- 08Ozkizilcik A, et al. Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease. Progress in brain research. 2019;245:201-246. PMID: 30961868.
- 09Fiani B, et al. Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2021;42(4):1345-1353. PMID: 33515100.
- 10Plosker GL, et al. Cerebrolysin: a review of its use in dementia. Drugs & aging. 2009;26(11):893-915. PMID: 19848437.
- 11Vester JC, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2021;42(11):4531-4541. PMID: 33620612.
- 12Kalinin MN, et al. [Cerebrolysin as an early add-on to reperfusion therapy: heterogeneous treatment effect analysis in ischemic stroke patients with varying risk of hemorrhagic transformation]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2024;124(3. Vyp. 2):55-66. PMID: 38512096.
- 13Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2010(4):CD007026. PMID: 20393954.
- 14Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. The Cochrane database of systematic reviews. 2016;12(12):CD007026. PMID: 27918088.
- 15iganshina LE, et al. [Cerebrolysin for acute ischemic stroke]. Vestnik Rossiiskoi akademii meditsinskikh nauk. 2013(1):21-9. PMID: 23805635.
- 16Gavrilova SI, et al. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use. Medicinal research reviews. 2021;41(5):2775-2803. PMID: 32808294.
- 17Torshin IY, et al. [Cerebrolysin peptides as mood stabilizers]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(12):69-75. PMID: 31994517.
- 18Gauthier S, et al. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dementia and geriatric cognitive disorders. 2015;39(5-6):332-47. PMID: 25832905.
- 19Wang Z, et al. Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials. Drug design, development and therapy. 2017;11:1273-1282. PMID: 28458521.
- 20Bogolepova AN. [Cerebrolysin in the treatment of cognitive impairment]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2023;123(3):20-25. PMID: 36946392.
- 21Villarreal-Reyna G, et al. Cerebrolysin induces hair repigmentation associated to MART-1/Melan-A reactivation. European journal of medical research. 2022;27(1):257. PMID: 36411485.
- 22Allegri RF, et al. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia. Drugs of today (Barcelona, Spain : 1998). 2012;48 Suppl A:25-41. PMID: 22514793.
- 23Fiani B, et al. Neuroprotective strategies of cerebrolysin for the treatment of infants with neonatal hypoxic-ischemic encephalopathy. Acta neurologica Belgica. 2021;121(6):1401-1406. PMID: 34494216.
- 24Sharma A, et al. Nanowired Delivery of Cerebrolysin Together with Antibodies to Amyloid Beta Peptide, Phosphorylated Tau, and Tumor Necrosis Factor Alpha Induces Superior Neuroprotection in Alzheimer's Disease Brain Pathology Exacerbated by Sleep Deprivation. Advances in neurobiology. 2023;32:3-53. PMID: 37480458.
- 25Sharma HS, et al. Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease. Progress in brain research. 2019;245:145-200. PMID: 30961867.
- 26Homberg V, et al. Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study. Stroke. 2025;56(4):937-947. PMID: 39957612.
- 27Staszewski J, et al. Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study. Translational stroke research. 2025;16(6):1931-1946. PMID: 40325343.
- 28Menon PK, et al. Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals. CNS & neurological disorders drug targets. 2012;11(1):40-9. PMID: 22229324.
- 29Sarode LP, et al. Cerebrolysin reduces excitotoxicity by modulation of cell-death proteins in delayed hours of ischemic reperfusion injury. Metabolic brain disease. 2023;38(7):2401-2416. PMID: 37273080.
- 30Rejdak K, et al. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin. Medicinal research reviews. 2023;43(5):1668-1700. PMID: 37052231.
- 31Tonge C, et al. Cerebrolysin Amelioration of Spinal Cord Ischemia/ Reperfusion Injury in Rabbit Model. Turkish neurosurgery. 2023;33(6):1017-1027. PMID: 37309634.
- 32Wan M, et al. Efficacy, safety, and cost-effectiveness analysis of Cerebrolysin in acute ischemic stroke: A rapid health technology assessment. Medicine. 2024;103(13):e37593. PMID: 38552072.
- 33Kojder K, et al. Cerebrolysin in Patients Diagnosed with Subarachnoid Hemorrhage-The Results of an Observational Cohort Study. Biomedicines. 2024;12(11). PMID: 39595058.
- 34Al-Kuraishy HM, et al. The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts. Neuroscience. 2025;568:202-208. PMID: 39832667.
- 35Thome J, et al. Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials. Drugs of today (Barcelona, Spain : 1998). 2012;48 Suppl A:63-9. PMID: 22514795.
- 36Sharma HS, et al. Neuroprotective Effects of Nanowired Delivery of Cerebrolysin with Mesenchymal Stem Cells and Monoclonal Antibodies to Neuronal Nitric Oxide Synthase in Brain Pathology Following Alzheimer's Disease Exacerbated by Concussive Head Injury. Advances in neurobiology. 2023;32:139-192. PMID: 37480461.
- 37Bornstein NM, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2018;39(4):629-640. PMID: 29248999.
- 38Zhang D, et al. Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials. BioMed research international. 2017;2017:4191670. PMID: 28656143.
- 39Alzoubi KH, et al. Cerebrolysin prevents sleep deprivation induced memory impairment and oxidative stress. Physiology & behavior. 2020;217:112823. PMID: 31987894.
- 40Antón Álvarez X, et al. Cerebrolysin in Alzheimer's disease. Drugs of today (Barcelona, Spain : 1998). 2011;47(7):487-513. PMID: 22013558.
- 41Strilciuc S, et al. Cost-effectiveness of Cerebrolysin as an add-on treatment for neurorecovery after traumatic brain injury. Journal of medicine and life. 2025;18(4):387-392. PMID: 40405935.
- 42Abdelaty AO, et al. Cerebrolysin potentiates the antidepressant effect of lithium in a rat model of depression. Journal of psychiatric research. 2024;172:171-180. PMID: 38394763.
- 43Ozkizilcik A, et al. Nanowired delivery of antibodies to tau and neuronal nitric oxide synthase together with cerebrolysin attenuates traumatic brain injury induced exacerbation of brain pathology in Parkinson's disease. International review of neurobiology. 2023;171:83-121. PMID: 37783564.
- 44Yazar U, et al. Cerebrolysin provides effective protection on high glucose-induced neuropathy in cultured rat dorsal root ganglion neurons. Journal of receptor and signal transduction research. 2023;43(5):109-114. PMID: 38079610.
- 45Guekht A, et al. Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2017;38(10):1761-1769. PMID: 28707130.
- 46Sharma HS, et al. Alzheimer's disease: cerebrolysin and nanotechnology as a therapeutic strategy. Neurodegenerative disease management. 2016;6(6):453-456. PMID: 27827552.
- 47Wei ZH, et al. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. Journal of neural transmission (Vienna, Austria : 1996). 2007;114(5):629-34. PMID: 17318304.
- 48Wiklund L, et al. TiO(2)-Nanowired Delivery of Chinese Extract of Ginkgo biloba EGb-761 and Bilobalide BN-52021 Enhanced Neuroprotective Effects of Cerebrolysin Following Spinal Cord Injury at Cold Environment. Advances in neurobiology. 2023;32:353-384. PMID: 37480466.
- 49Khasanova DR, et al. Cerebrolysin as an Early Add-on to Reperfusion Therapy: Risk of Hemorrhagic Transformation after Ischemic Stroke (CEREHETIS), a prospective, randomized, multicenter pilot study. BMC neurology. 2023;23(1):121. PMID: 36973684.
- 50Kang DH, et al. Effects of Cerebrolysin on Hippocampal Neuronal Death After Pilocarpine-Induced Seizure. Frontiers in neuroscience. 2020;14:568813. PMID: 33177978.
- 51Mafikandi V, et al. Effects of cerebrolysin on behavioral changes and the tryptophan-kynurenine pathway in the prefrontal cortex of male mice in the ketamine model of schizophrenia. Molecular biology reports. 2025;52(1):723. PMID: 40668305.
- 52Muresanu DF, et al. Diabetes exacerbates brain pathology following a focal blast brain injury: New role of a multimodal drug cerebrolysin and nanomedicine. Progress in brain research. 2020;258:285-367. PMID: 33223037.
- 53Sharma A, et al. Sleep deprivation exacerbates concussive head injury induced brain pathology: Neuroprotective effects of nanowired delivery of cerebrolysin with α-melanocyte-stimulating hormone. Progress in brain research. 2019;245:1-55. PMID: 30961865.
- 54Zhang Y, et al. Cerebrolysin Reduces Astrogliosis and Axonal Injury and Enhances Neurogenesis in Rats After Closed Head Injury. Neurorehabilitation and neural repair. 2019;33(1):15-26. PMID: 30499355.
- 55Martínez-Torres NI, et al. Cerebrolysin Induces Motor Recovery Along with Plastic Changes in Motoneurons and an Increase in GAP43 Protein in the Ventral Spinal Cord Following a Kainic Acid Excitotoxic Lesion in the Rat Motor Cortex. Neurochemical research. 2024;50(1):31. PMID: 39580783.
- 56Aguilar-Hernández L, et al. Cerebrolysin ameliorates prefrontal cortex and hippocampus neural atrophy of spontaneous hypertensive rats with hyperglycemia. Synapse (New York, N.Y.). 2020;74(9):e22156. PMID: 32232874.
- 57Sharma HS, et al. Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. Progress in brain research. 2021;265:1-97. PMID: 34560919.
- 58Ponomareva EV, et al. [Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a three-year prospective comparative study]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2024;124(9):51-59. PMID: 39435777.
- 59Sharma A, et al. Mild traumatic brain injury exacerbates Parkinson's disease induced hemeoxygenase-2 expression and brain pathology: Neuroprotective effects of co-administration of TiO(2) nanowired mesenchymal stem cells and cerebrolysin. Progress in brain research. 2020;258:157-231. PMID: 33223035.
- 60Selezneva ND, et al. [Cerebrolysin Treatment Reduces the Risk of Mild Cognitive Decline to Dementia in 1st-Degree Relatives of Alzheimer's Patients: A Prospective Comparative Study]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2023;123(8):90-97. PMID: 37655416.
Learn about these too.
We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.
Want the rest of the peptide world, in plain English?
New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.